Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Immunotherapy in Localized Colorectal Cancer: Current Practice and Future Directions.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Ensuring the Future of Cooperative Group Cancer Clinical Trials: A Call for Comprehensive Support and Prioritization.

JCO oncology practice·2026
Same author

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Clinical, manometric, genetic, and histologic associations in pediatric intestinal pseudo-obstruction: A case series.

Journal of pediatric gastroenterology and nutrition·2026
Same author

Preoperative 24-hour movement behaviors and early weight loss after metabolic bariatric surgery: a compositional analysis.

International journal of obesity (2005)·2025
Same author

Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.

Cancer research communications·2025
Same journal

Development and Validation of Salivary Exosomal Tri-RNA Liquid Biopsy in Esophageal Carcinoma: A Multicenter Study.

JCO precision oncology·2026
Same journal

Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment.

JCO precision oncology·2026
Same journal

Integrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers: A Pan-Cancer Analysis.

JCO precision oncology·2026
Same journal

Sustained Response to Trametinib in Central Giant Cell Granuloma With <i>KRAS</i> Gain-of-Function Mutation: A Case Report.

JCO precision oncology·2026
Same journal

DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers.

JCO precision oncology·2026
Same journal

Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.

JCO precision oncology·2026
查看所有相关文章

相关实验视频

Updated: Jun 9, 2025

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

13.2K

使用人工智能来支持关于BRAF突变测试的知情决策.

Jennifer Webster1, Jennifer Ghith1, Orion Penner2

  • 1Pfizer Inc, New York, NY.

JCO precision oncology
|October 30, 2024
PubMed
概括
此摘要是机器生成的。

开发了一个人工智能平台来分析癌症中的BRAFV600突变率. 虽然人工智能显示了强大的过,但手动审查显示了报告中的不一致性,突出了对精确瘤学的标准化数据的需求.

更多相关视频

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

1.3K
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

967

相关实验视频

Last Updated: Jun 9, 2025

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

13.2K
Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

1.3K
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

967

科学领域:

  • 生物医学信息学 生物医学信息学
  • 在瘤学瘤学.
  • 计算生物学 计算生物学

背景情况:

  • 精确瘤学需要准确报告生物标志物测试和突变率.
  • 在结直肠癌,非小细胞肺癌和黑色素瘤中,BRAFV600突变至关重要.

研究的目的:

  • 开发一个人工智能和NLP管道,用于从文献中注释BRAFV600测试和突变率.
  • 创建一个交互式平台,探索不同癌症类型的这些病率.

主要方法:

  • 利用人工智能识别和过报告测试或突变率的相关出版物.
  • 雇佣专家进行数据验证的手动策划.
  • 使用精度和回忆指标评估AI性能.

主要成果:

  • 开发了一个交互式仪表板,以可视化注释的BRAFV600突变和测试率.
  • 人工智能实现了>90%的精度和回忆,用于出版过.
  • 手动注释显示了评估者之间显著的分歧 (19%用于测试,70%用于突变率),表明报告不一致.

结论:

  • 人工智能驱动的NLP对标注生物标志物率显示出希望.
  • 不一致的报告需要改进人工智能驱动的文献搜索和标准化的数据呈现.
  • 标准化将加强临床决策和精密瘤学的研究.